Search filters

List of works by Daniel A Pollyea

Acute myeloid leukemia drug development in the post-venetoclax era

scientific article published on 25 June 2019

CD123 CAR T cells for the treatment of myelodysplastic syndrome

scientific article published on 25 May 2019

Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes

scientific article published in Nature Communications

Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study

scientific article

Cysteine depletion targets leukemia stem cells through inhibition of electron transport complex II

scientific article published on 17 May 2019

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

scientific article

Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia

scientific article published on 09 April 2019

Genomic landscape of neutrophilic leukemias of ambiguous diagnosis

scientific article published on 31 July 2019

How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia

scientific article published on 18 October 2019

Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia

scientific article published on 23 January 2020

Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML

scientific article

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

scientific article published on 16 December 2018

Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes

scientific article published on 21 November 2020

Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study

scientific article published on 16 March 2020

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

scientific article published on 12 January 2018

The hepatic microenvironment uniquely protects leukemia cells through induction of growth and survival pathways mediated by LIPG

scientific article published on 07 October 2020

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

scholarly article by Courtney D DiNardo et al published 25 October 2018 in Blood

Venetoclax for AML: changing the treatment paradigm

scientific article published on 01 December 2019

Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia

scientific article published on 12 November 2018

Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a Phase 1b study

scientific article published on 29 October 2020